Multifunctional Iron Oxide Nanostructures for MRI Contrast and Photothermal Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current MRI contrast agents face limitations such as toxicity concerns with gadolinium-based agents and decreased T1 relaxivity at higher magnetic field strengths, necessitating the development of alternative materials that can provide enhanced imaging and therapeutic capabilities while minimizing adverse effects.
Innovation Solution
The creation of multifunctional nanostructures comprising a metal core, dielectric shell, and metal shell, which include MRI contrast agents and fluorophores, allowing for targeted imaging and photothermal therapy, with a focus on using iron-based contrast agents that offer improved relaxivity and reduced toxicity, and incorporating chelating agents to stabilize and concentrate MRI active materials within the nanostructures.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If gadolinium-based contrast agents are used to enhance MRI imaging, then imaging contrast is improved, but toxicity concerns increase
Solution Approach 1:
The patent uses iron oxide nanoparticles as an intermediary contrast agent that provides the necessary MRI contrast enhancement without the toxicity issues of gadolinium. The iron oxide particles serve as a mediator between the imaging requirement and safety concern, delivering T2 contrast enhancement through magnetic susceptibility effects while being biocompatible and clearance-friendly.
Solution Approach 2:
The patent changes the fundamental parameter of contrast agent composition from gadolinium-based to iron oxide-based, fundamentally altering the chemical nature of the contrast agent. This parameter change shifts the mechanism from paramagnetic gadolinium ions to superparamagnetic iron oxide particles, achieving similar contrast enhancement through different physical principles while eliminating toxicity concerns.
2Measurement precision
If conventional MRI contrast agents are used, then imaging is achieved, but relaxivity decreases at higher magnetic field strengths
Solution Approach 1:
The patent substitutes the T1 relaxation mechanism (dependent on paramagnetic ions like gadolinium) with a T2 relaxation mechanism based on magnetic susceptibility effects of iron oxide particles. This substitution replaces a mechanism that degrades at high fields with one that remains effective or even improves, as the magnetic susceptibility contrast scales with field strength.
3Adaptability or versatility
If multifunctional nanostructures are created to provide both imaging and therapy, then versatility is improved, but device complexity increases
Solution Approach 1:
The patent merges imaging and therapeutic functions into a single iron oxide nanoparticle platform. The same particle that provides T2 MRI contrast enhancement also serves as a photothermal therapy agent when illuminated with near-infrared light, and can carry surface-bound therapeutics. This merging eliminates the need for separate imaging and therapy agents, reducing overall system complexity despite the multifunctionality.
Solution Approach 2:
The iron oxide nanoparticle is designed as a universal platform that simultaneously performs multiple functions: T2 MRI contrast enhancement, photothermal therapy, and potential drug delivery. The universal nature of this platform allows it to replace multiple separate agents, simplifying the overall therapeutic and diagnostic regimen despite the enhanced capabilities.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These nanostructures enhance MRI contrast and relaxivity, reduce toxicity, and enable effective photothermal therapy, with improved stability and prolonged imaging time, while allowing for real-time tracking and precise anatomical monitoring, thus addressing the limitations of existing agents.
Implementation Method 1
Contrast agents for MRI lighten or darken MRI phantoms by modifying the relaxation time of the spins of protons in water
Implementation Method 2
enable effective photothermal therapy
Data Source
AI summary
A Magnetic Resonance Imaging (MRI) enhancement agent includes a plurality of particles, each particle including: a metal core; a dielectric shell disposed on the metal core comprising at least one MRI contrast agent; and a metal shell disposed on the exterior surface of the dielectric shell that encapsulates the dielectric shell.